Vitranu is developing a Tunable Extended Release Capsule (TERC™) for sustained delivery of therapeutics to the eye via intravitreal injection. TERC™ is manufactured with biodegradable polymers using novel electrospinning technology to produce a double-walled, tunable capsule that can be filled with unaltered biologic or small molecule therapeutics.
By modifying the electrospinning process parameters, capsules can be made with defined pore sizes and "tuned" to deliver the payload with the desired drug elution profile. This patented and unique approach provides a platform technology to fulfill the unmet need of sustained, controllable ophthalmic drug delivery.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 7720 Rivers Edge Dr,
- Industry
- Biotechnology
- Website
- https://www.vitranu.com
- Keywords
- Ophthalmology, AMD, Drug Delivery, Age-related Macular Degeneration, Retinal Disease, TERC, Therapeutics, Treatment.
- HQ
- Columbus, Ohio
Vitranu Questions
Vitranu's website is https://www.vitranu.com
Vitranu's LinkedIn profile is https://www.linkedin.com/company/vitranu
Vitranu has
5 employees.
View email and phone details for 5
employees at Vitranu.
Vitranu's industry is
Biotechnology
Vitranu's top competitors are
Resilient Medical Corp,
Avionova,
Grai Matter,
Mediview Xr, Inc.,
Viyamd,
Acuity Medical,
Myoptechs,
Lentechs,
Tegosens,
Inovcares.
Vitranu's categories are Biotechnology
Vitranu's founding year is 2020
